Analysis of homologous recombination deficiency testing in ovarian cancer based on next-generation sequencing
DNA sequencing accurately identifies ovarian cancer patients who benefit from PARP inhibitors without needing multiple tests.
This study evaluates the clinical performance of NGS-based homologous recombination deficiency testing in ovarian cancer, demonstrating its ability to accurately classify HRD status and identify PARP inhibitor candidates. Findings support broad NGS-based HRD implementation as a standard companion diagnostic in ovarian cancer precision medicine.
What the study was
- Study design
- Clinical validation study
- Population
- Ovarian cancer patients undergoing NGS-based HRD testing for PARP inhibitor eligibility
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Zhonghua zhong liu za zhi [Chinese journal of oncology]
Why it surfaced
NGS-based HRD testing validation in ovarian cancer; important companion diagnostic for PARP inhibitor eligibility in a high-mortality gynecological malignancy.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.